Skip to content

Genetic Screening and Assisted Oocyte Activation in Couples with Diminished/aberrant Embryonic Development.

Genetic Screening and Investigating the Effect of Assisted Oocyte Activation in Couples with Diminished/aberrant Embryonic Development.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03354013
Acronym
AOA
Enrollment
42
Registered
2017-11-27
Start date
2018-01-15
Completion date
2022-09-09
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Embryo, Embryo Disorder, Genetic Disease

Keywords

AOA, embryo developmental problems, genetic screening, calcium pattern analysis

Brief summary

This is an interventional comparative study at the Department of Reproductive Medicine at Ghent University Hospital. Patients with previous embryo developmental problems are eligible for the study. Patients will undergo an ICSI-AOA treatment and will also be screened for genes important in the oocyte activation and embryonic development process. Also, the calcium releasing pattern of the patients' spermatozoa will be investigated.

Detailed description

Assisted Oocyte Activation (ICSI-AOA) will be the treatment for these patients to overcome their previous embryo developmental problems. This protocol artificially induces calcium rises in the oocyte, which mimics the natural oocyte activation process induced by the sperm factor PLCzeta. If 6 or more mature oocytes are collected at oocyte retrieval, 50%ICSI and 50% ICSI-AOA will be applied to all oocytes. The best embryo(s) will be transferred back. Rest embryo(s) will be vitrified for future cycles. Patients will be followed up. Furthermore, an additional sperm sample will be produced to investigate the calcium inducing pattern of the patients' spermatozoa. Thereby, mouse and/or human (research-donated control oocytes) will be pre-incubated with a Ca2+ sensitive dye. Next, human spermatozoa will be injected into these mouse/human oocytes and the calcium pattern will be recorded under an inverted epifluorescence microscope. Both partners will give a saliva sample to screen for mutations possible genes involved in oocyte activation and embryo development.

Interventions

PROCEDUREAOA

100% ICSI-AOA will be performed.

DIAGNOSTIC_TESTGenetic screening

Patients will donate a saliva sample. Genetic screening will take place for PLCzeta (male) and Dux4 (male and female). Also other possible genes involved in embryo development could be tested.

DIAGNOSTIC_TESTCalcium pattern analysis

Male patients will donate a sperm sample. Calcium pattern analysis will take place by injecting the patients' sperm into mouse and/or human (in vitro matured) oocytes (research-donated control oocytes). This will estimate the sperm capability to induce calcium oscillations in the oocyte.

Sponsors

University Hospital, Ghent
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients with one or more previous ICSI cycles (UZ Gent) AND * patients with: * complete developmental arrest (no transfer), or * complete developmental delay (no morula/blastocyst on Day 5), or * significantly reduced blastocyst formation (≤15%) * willing and able to give informed consent

Exclusion criteria

* patients which went for oocyte or sperm donation * patients with severe male infertility or low fertilization (\<33%) after ICSI * cycles requiring surgical sperm recovery procedures

Design outcomes

Primary

MeasureTime frameDescription
Blastocyst rate5 days after oocyte retrievalBlastocyst rate will be calculated and blastocyst will be scored. The best quality embryos will be transferred and/or frozen.

Secondary

MeasureTime frameDescription
Pregnancy ratePositive hCG 16 days after oocyte retrievalThe level of beta-hCG in serum will be checked 16 days after oocyte retrieval
Live birth rate37 - 42 weeks after last menstruationPregnant women will be followed up. Live births will be recorded.

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026